How to Cite
Abstract
Liquid biopsy is a promising approach to molecular tumor testing in the context of targeted therapy. During this pilot study we applied a high-sensitivity protocol for detection of tumor-derived mutations in circulating plasma DNA of EGFR-positive non-small cell lung cancer (NSCLC) patients during EGFR-TKI therapy. We showed that this protocol was well suited for dynamic monitoring during targeted therapy as well as for detection of acquired resistance mutations.References
Brugger W., Triller N., Blasinska-Morawiec M., et al. Prospective molecular marker analyses of EGFR and KRAs from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer // J Clin Oncol. - 2011. - Vol. 29 (31). -P 4113-4120.
Chmielecki J., Foo J., Oxnard GR. et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling // Sci Transl Med. - 2011. -Vol. 6 (90):90ra59. doi: 10. 1126/scitranslmed. 3002356.
Cushman-Vokoun A. M. et al. Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays formutation analysis in non-small cell lung cancer // Am J Clin Pathol. - 2013. - Vol. 140 (1). - P 7-19.
Do H., et al. Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates // Clin Chem. - 2013. - Vol. 59 (9). - P. 1376-1383.
Hata, A., et al. Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-MutantNon-small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI // J Thorac Oncol. - 2015. - Vol. 10 (11). - P 1553-1559.
Kobayashi S., Boggon T. J., Dayaram T. et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib // N Engl J Med. - 2005. - Vol. 352. - P 786-792.
Kuang Y., Rogers A., Yeap B. Y. M., et al. (2009) Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant nonsmall cell lung cancer // Clin Cancer Res. - 2009. -Vol. 15. - P. 2630-2636.
Levy B. P., et al. Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations // Oncologist. -2015. - Vol. 20 (10). - P 1175-1181.
Luo J., Shen L., Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis // Sci Re. -2014-. - Vol. 4. - P. 6269.
Mok T., Wu Y. L., Lee J. S. et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy // Clin Cancer Res. 2015. - Vol. 15 (14). - P 3196-3203.
Overman M. J., Modak J., Kopetz S. et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? // J Clin Oncol. - 2013. - Vol. 31 (1). - P. 17-22.
Oxnard G. R., Arcila M. E., Sima C. S. et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation // Clin Cancer Res. - 2011. - Vol. 17. - P. 1616-1622.
Qiu M., Wang J., Xu Y. et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis // Cancer Epidemiol Biomarkers Prev. - 2015. - Vol. 24 (1). - P. 206-212.
Rosell R., Molina M. A., Costa C. et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced nonsmall-cell lung cancer patients with EGFR mutations // Clin Cancer Res. - 2011. - Vol. 17. - P. 1160-1168.
Rosell R., Carcereny E., Gervais R. et al. Erlotinib versus standard chemotherapy as fi rst-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial // Lancet Oncol. - 2012. Vol. 13. - P 239-246.
Sequist L. V., Martins R. G., Spigel D. et al. Firstline gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations // J Clin Oncol. - 2008. - Vol. 26. - P 2442-2449.
Sharma S. V., Bell D. W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer // Nat Rev Cancer. - 2007. - Vol. 7 (3). -P. 169-181.
Sun W., Yuan X., Tian Y. et al. Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer // J Hematol Oncol. - 2015. - Vol. 8. - P. 95.
Wang, S., et al. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer // J Hematol Oncol. - 2016. - Vol. 12 (1). - P. 34.
Wang Z., Chen R., Wang S. et al. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC // PLoS One. - 2014. - Vol. 18 (11). - P. 110780.
Yung T. K., Chan K. C., Mok T. S. et al. (2009) Singlemolecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in nonsmall cell lung cancer patients // Clin Cancer Res. -2009. - Vol. 15. - P 2076-2084.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...